TiumBio Co., Ltd.
Biopharmaceutical firm developing therapeutics for rare and incurable diseases.
321550 | KO
Overview
Corporate Details
- ISIN(s):
- KR7321550006
- LEI:
- Country:
- South Korea
- Address:
- 경기도 성남시 수정구 창업로40번길 30 6층 (시흥동, 판교아이티센터), 성남시
- Website:
- http://www.tiumbio.com/en/
Description
TiumBio is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapeutics for rare and incurable diseases. The company's pipeline targets conditions with high unmet medical needs, including fibrotic diseases, cancer, and rare hematological disorders. Its lead assets include Merigolix (TU2670), an oral GnRH antagonist in clinical development for endometriosis and uterine fibroids, and TU7710, a long-acting recombinant activated factor VII for hemophilia. TiumBio also develops small molecule antagonists targeting the TGF-β signaling pathway for applications in oncology and fibrosis. The company advances its programs through clinical development and strategic global partnerships.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2021-05-11 00:00 |
투자판단관련주요경영사항(자궁내막증 치료제 TU2670의 폴란드 임상 2a상 시험 계획 승인)
|
Korean | 11.1 KB | ||
| 2021-04-16 00:00 |
투자판단관련주요경영사항(자궁내막증 치료제 TU2670의 체코 임상 2a상 시험 계획 승인)
|
Korean | 11.0 KB | ||
| 2021-04-02 00:00 |
주식등의대량보유상황보고서(일반)
|
Korean | 128.1 KB | ||
| 2021-03-29 00:00 |
정기주주총회결과
|
Korean | 33.3 KB | ||
| 2021-03-29 00:00 |
사외이사의선임ㆍ해임또는중도퇴임에관한신고
|
Korean | 13.9 KB | ||
| 2021-03-29 00:00 |
주식매수선택권부여에관한신고
|
Korean | 18.3 KB | ||
| 2021-03-19 00:00 |
사업보고서 (2020.12)
|
Korean | 295.0 KB | ||
| 2021-03-19 00:00 |
감사보고서제출
|
Korean | 24.2 KB | ||
| 2021-03-16 00:00 |
의결권대리행사권유참고서류
|
Korean | 278.2 KB | ||
| 2021-03-12 00:00 |
주주총회소집공고
|
Korean | 269.1 KB | ||
| 2021-03-12 00:00 |
주주총회소집결의
|
Korean | 22.0 KB | ||
| 2021-02-19 00:00 |
투자판단관련주요경영사항(자궁내막증 치료제 TU2670의 이탈리아 임상 2a상 시험 계획 신청)
|
Korean | 13.0 KB | ||
| 2021-02-15 00:00 |
매출액또는손익구조30%(대규모법인은15%)이상변동
|
Korean | 11.3 KB | ||
| 2021-02-04 00:00 |
투자판단관련주요경영사항(자궁내막증 치료제 TU2670의 폴란드 임상 2a상 시험 계획 신청)
|
Korean | 12.6 KB | ||
| 2020-12-18 00:00 |
주식등의대량보유상황보고서(일반)
|
Korean | 143.6 KB |
Automate Your Workflow. Get a real-time feed of all TiumBio Co., Ltd. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for TiumBio Co., Ltd.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for TiumBio Co., Ltd. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
